Pharming Group (PHGUF)
(Delayed Data from OTC)
$0.75 USD
-0.07 (-8.51%)
Updated Sep 4, 2024 02:25 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Pharming Group NV [PHGUF]
Reports for Purchase
Showing records 1 - 20 ( 142 total )
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
3Q20 Results; Ruconest Pushes Forward; U.S. a Key Driver
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
COVID-19 Study Gets Rolling as Expected; Being Thoughtful and Following the Science
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
2Q20 Recap - Moving Forward Despite COVID-19 Challenges
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
1H20 Results; Business Is Cranking Across the Board; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
1Q20 Results; Ruconest Continues to Deliver
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
Rounding out the E.U. Market; Ruconest Approved for Pediatric Use; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
Attacking COVID-19 Inflammation With Ruconest; Early Positive Data Prompts Planned Randomized Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
FDA Site Approval Boosts Our Confidence in Ruconest''s Expansion Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
Business Is Cranking; Believe Still Just Scratching Surface of Upcoming Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
Nice Year End Chess Move Leveraging Significant Commercial Experience
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
3Q19 Results; Ruconest Continues to Grow and Support Pipeline Expansion; Target Upped to EUR 3.10
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
3Q19 Recap - Solid Quarter and Expanded Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Pharming Group NV
Industry: Medical - Biomedical and Genetics
Expanding Portfolio Opportunity Beyond Ruconest; Nice Potential Valuation Add in Back Pocket; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J